Conformationally constrained Smac mimetics and the uses thereof
View Patent ↗The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
1. A compound having Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is NR 1 R 2 , or N + R 1 R 2 R 3 ;
R 1 , R 2 , and R 3 are independently hydrogen or optionally substituted C 1-8 alkyl, C 2-8 alkenyl, or C 2-8 alkynyl, in which one or more carbons can be replaced by C═O, C═S, or a heteroatom selected from O, S, and N, and one or more hydrogens in CH, CH 2 or CH 3 groups can be replaced by fluorine, a branched or unbranched alkyl or cycloalkyl, an optionally substituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl, or OR 4 , SR 4 , or NR 4 R 5 ;R 4 , and R 5 are independently hydrogen or optionally substituted C 1-4 alkyl, C 2-5 alkenyl, or C 2-5 alkynyl, in which one or more carbons can be replaced by a heteroatom selected from O, S, and N, or optionally substituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl; or
any two of R 1 , R 2 , and R 3 taken together with the nitrogen to which they are attached form a heterocyclic group, in which one or more carbon atom can be replaced by C═O, C═S, or a heteroatom selected from O, S, and N, with the proviso that the heteroatom is separated from the nitrogen atom by at least two carbons;
B is optionally substituted C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl, wherein one or more hydrogens can be replaced by fluorine;
U is CONH, C(O)O, C(S)O, C(S)NH, C(NH)NH, or (CH 2 ) 1-5 , wherein one or more carbons can be replaced by a heteroatom selected from O, S, and N;
V and W are independently (CH 2 ) 1-5 , wherein one or more carbons can be replaced by C═O, C═S, or a heteroatom selected from O, S, and N, and one or more hydrogens in CH 2 groups can be replaced by a branched or unbranched alkyl or cycloalkyl, an optionally substituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl, or OR 4 , SR 4 , or NR 4 R 5 ;
X is optionally substituted C 1-18 alkyl, C 2-18 alkenyl, C 2-18 alkynyl, aryl, or heteroaryl, wherein one or more carbons can be replaced by C═O, C═S, or a heteroatom selected from O, S, and N, and one or more hydrogens in CH, CH 2 or CH 3 groups can be replaced by a branched or unbranched alkyl or cycloalkyl, an optionally substituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl, or OR 4 , SR 4 , or NR 4 R 5 ; Y is N and forms a bicyclic ring system with one of the ring being a seven-membered ring;
Z is CH 2 , C═O, C═S, CHSR, CHOR, or CHNR; and
R is hydrogen or optionally substituted C 1-4 alkyl, C 2-4 alkenyl, or C 2-4 alkynyl.
2. The compound of claim 1 , having formula IV:
3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3 , wherein said compound has formula IV: